Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857866 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04857866 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 48 participants.
The verdict
NCT04857866, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending-dose study of subcutaneously administered XmAb27564 or placebo in healthy male and female subjects.
Interventions
- DRUG Placebo
- DRUG XmAb27564
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-04-19 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857866
The ClinicalTrials.gov registry entry for NCT04857866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04857866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04857866 about?
NCT04857866 is a clinical study titled "Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers". This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending-dose study of subcutaneously administered XmAb27564 or placebo in healthy male and female subjects.
What is the current status of trial NCT04857866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-04-19. Estimated completion is 2022-11-10.
What interventions are being tested in trial NCT04857866?
The interventions under investigation include: Placebo (DRUG), XmAb27564 (DRUG).
Who is sponsoring clinical trial NCT04857866?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.